<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" 
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:wfw="http://wellformedweb.org/CommentAPI/"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:meneame="http://meneame.net/faq-es.php"
 >
<channel>
	<title>Menéame: comentarios [3563913]</title>
	<link>http://www.meneame.net</link>
	<image><title>www.meneame.net</title><link>http://www.meneame.net</link><url>http://cdn.mnmstatic.net/img/mnm/eli-rss.png</url></image>
	<description>Sitio colaborativo de publicación y comunicación entre blogs</description>
	<pubDate>Fri, 01 Oct 2021 13:01:32 +0000</pubDate>
	<generator>http://blog.meneame.net/</generator>
	<language>es</language>
	<item>
		<meneame:comment_id>34027482</meneame:comment_id>
		<meneame:link_id>3563913</meneame:link_id>
		<meneame:order>4</meneame:order>
		<meneame:user>Nitanmal</meneame:user>
		<meneame:votes>0</meneame:votes>
		<meneame:karma>7</meneame:karma>
		<meneame:url>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid</meneame:url>
		<title>#4 El antiviral molnupiravir reduce a la mitad el riesgo de hospitalización o muerte por COVID-19</title>
		<link>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c04#c-4</link>
		<pubDate>Fri, 01 Oct 2021 13:01:32 +0000</pubDate>
		<dc:creator>Nitanmal</dc:creator>
		<guid>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c04#c-4</guid>
		<description><![CDATA[<p>Molnupiravir mezclado a partes iguales con sangre de llama (virgen extra) y un porrito de CBD aseguran inmunidad vitalicia</p><p>&#187;&nbsp;autor: <strong>Nitanmal</strong></p>]]></description>
	</item>

	<item>
		<meneame:comment_id>34027480</meneame:comment_id>
		<meneame:link_id>3563913</meneame:link_id>
		<meneame:order>3</meneame:order>
		<meneame:user>--655327--</meneame:user>
		<meneame:votes>0</meneame:votes>
		<meneame:karma>8</meneame:karma>
		<meneame:url>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid</meneame:url>
		<title>#3 El antiviral molnupiravir reduce a la mitad el riesgo de hospitalización o muerte por COVID-19</title>
		<link>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c03#c-3</link>
		<pubDate>Fri, 01 Oct 2021 13:01:28 +0000</pubDate>
		<dc:creator>--655327--</dc:creator>
		<guid>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c03#c-3</guid>
		<description><![CDATA[<p><a class="tooltip c:3563913-1" href="https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c01#c-1" rel="nofollow">#1</a> es la manera de poder obtener datos científicos en fase experimental y medir la efectividad del nuevo fármaco.</p><p>&#187;&nbsp;autor: <strong>--655327--</strong></p>]]></description>
	</item>

	<item>
		<meneame:comment_id>34027452</meneame:comment_id>
		<meneame:link_id>3563913</meneame:link_id>
		<meneame:order>2</meneame:order>
		<meneame:user>--673917--</meneame:user>
		<meneame:votes>0</meneame:votes>
		<meneame:karma>12</meneame:karma>
		<meneame:url>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid</meneame:url>
		<title>#2 El antiviral molnupiravir reduce a la mitad el riesgo de hospitalización o muerte por COVID-19</title>
		<link>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c02#c-2</link>
		<pubDate>Fri, 01 Oct 2021 12:58:14 +0000</pubDate>
		<dc:creator>--673917--</dc:creator>
		<guid>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c02#c-2</guid>
		<description><![CDATA[<p><a class="tooltip c:3563913-1" href="https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c01#c-1" rel="nofollow">#1</a> Los ensayos clínicos se hacen con voluntarios, con consentimiento informado.</p><p>&#187;&nbsp;autor: <strong>--673917--</strong></p>]]></description>
	</item>

	<item>
		<meneame:comment_id>34027431</meneame:comment_id>
		<meneame:link_id>3563913</meneame:link_id>
		<meneame:order>1</meneame:order>
		<meneame:user>Moteplass</meneame:user>
		<meneame:votes>0</meneame:votes>
		<meneame:karma>7</meneame:karma>
		<meneame:url>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid</meneame:url>
		<title>#1 El antiviral molnupiravir reduce a la mitad el riesgo de hospitalización o muerte por COVID-19</title>
		<link>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c01#c-1</link>
		<pubDate>Fri, 01 Oct 2021 12:54:00 +0000</pubDate>
		<dc:creator>Moteplass</dc:creator>
		<guid>https://www.meneame.net/story/antiviral-molnupiravir-reduce-mitad-riesgo-hospitalizacion-covid/c01#c-1</guid>
		<description><![CDATA[<p>Eso de que te pongan placebo lo entiendo, pero que te lo pongan cuando te juegas la vida, no se yo.</p><p>&#187;&nbsp;autor: <strong>Moteplass</strong></p>]]></description>
	</item>

</channel>
</rss>
